Home

RSS Subscription Links

Clicking on an RSS link below will provide you with raw XML data of our content. If you do not have a compatible reader installed, you will see XML code in your browser - to view our content, paste the feed address into an RSS reader, or use a browser which supports RSS feeds. See below for additional information on RSS.
Press Release
RSS FeedsAll Press Releases
Event Calendar
RSS FeedsAll Calendar Events
SEC Filings
RSS FeedsAll SEC Filings
Additional Information About RSS
Really Simple Syndication (RSS) is an XML-based format for distributing and aggregating Web content (such as news headlines). Using RSS, web content providers can easily create and disseminate news headlines and URLs. To find more information about common RSS Readers, enter the term “RSS Reader” into an internet search engine.
Recommended RSS Readers
Omea Reader, Google Reader, Mozilla Thunderbird
Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.60
Change (%) Stock is Down 0.12 (16.67%)
Volume2,000
Data as of 05/17/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
May 15, 2013
Tengion Provides Business Update and Reports First Quarter 2013 Financial Results
-- Phase 1 trial of Neo-Kidney Augment™ on track for initiation in Sweden in second quarter of 2013 and in U.S. in fourth quarter of 2013 -- -- Actively recruiting for final three patients in Neo-Urinary Conduit™ trial -- WINSTON-SALEM, N.C., May 15, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013. "We are very pleased to have achieved a sig... 
April 01, 2013
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
WINSTON-SALEM, N.C., April 1, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the acceptance of the Company's Clinical Trial Application (CTA) filed with the Medical Products Agency (MPA) in Sweden to initiate a Phase 1 clinical trial to evaluate the safety and delivery of its Neo-Kidney Augment™ product in up to five patients with advanced chronic kidney disease (CKD).  "We are excited to have received MPA approval for the Neo-Kidney Augm...